Gilead and Leo Pact Adds Fuel To Hot STAT6 Inflammation Space
The US biotech is paying $250m upfront to the Danish group in what is the second STAT6 deal secured in the past three weeks.
The US biotech is paying $250m upfront to the Danish group in what is the second STAT6 deal secured in the past three weeks.